Altimmune heads to Barcelona for EASL26 to engage global liver disease specialists

Altimmune heads to Barcelona for EASL26 to engage global liver disease specialists
Altimmune heads to EASL26 Barcelona

Altimmune is set to participate in EASL26 in Barcelona, connecting with the international liver disease community.

The company invites attendees to visit its Medical Affairs team at booth D-40 to learn more about ongoing initiatives and access a list of planned presentations. Altimmune aims to strengthen its position within the sector through active engagement at the event.

Altimmune has previously called for early intervention and research on the connection between alcohol use disorder and liver disease in a recent statement. The company also released its first quarter 2026 financial results, providing a snapshot of recent performance. These efforts come as Altimmune continues to engage with the liver disease community.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.